Jiangsu Kanion Pharmaceutical Company Limited (“Kanion Pharmaceutical”) closed its A-share non-public offering on December 22th 2014, and introduced core management through an innovative asset management scheme, which laid a solid ground for Company to move towards the internationalization of modern Chinese medicine. In the deal, the Company issued approximately 14.93 million shares at RMB 24.11 / share, or 90% of the average trading price for the recent trading days prior to board resolution announcement, raising total proceeds of RMB 360 million. CICC acted as Sole Sponsor and Lead Underwriter.